Floatz logo

Trastuzumab Deruxtecan

Breast Carcinoma

SWOG Cancer Research Networkantibody_drug_conjugatePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

metastatic malignant neoplasm in the brainActive
BB
Indicative · Phase 4
66 / 100
View asset →
breast cancerActive
BB
Indicative · Phase 4
66 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →